HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hangzhou MSD Pharmaceutical Co. Ltd.

Division of Merck & Co. Inc.

Latest From Hangzhou MSD Pharmaceutical Co. Ltd.

Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant

Merck President of Global Human Health Adam Schechter talks about the company’s strategy in China and emerging markets following the opening of Merck’s $120 million plant in Hangzhou, China.

BioPharmaceutical China

Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant

Merck President of Global Human Health Adam Schechter talks about the company’s strategy in China and emerging markets following the opening of Merck’s $120 million plant in Hangzhou, China.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • HANGZHOU MSD EAST CHINA PHARMACEUTICAL CO. LTD.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Contact Info
  • Hangzhou MSD Pharmaceutical Co. Ltd.
    No. 864 Mo Gan Shan Road
    ,
    China
UsernamePublicRestriction

Register